Carregant...
Emerging agents and regimens for multiple myeloma
The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents a...
Guardat en:
| Publicat a: | J Hematol Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7654052/ https://ncbi.nlm.nih.gov/pubmed/33168044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00980-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|